Loading...

Gabriele Bergers, PhD

TitleProfessor
SchoolUCSF School of Medicine
DepartmentNeurological Surgery
Address1450 Third St
San Francisco CA 94158
Phone415-476-6786
vCardDownload vCard

    Collapse Research 
    Collapse Research Activities and Funding
    Inter-regulatory function of immune-modulation and angiogenesis in cancer
    NIH/NCI R01CA201537Aug 1, 2016 - Jul 31, 2021
    Role: Principal Investigator
    Autophagy as a microenvironmental regulator of tumorigenesis and resistance
    NIH/NCI R01CA188404Sep 1, 2014 - Aug 31, 2019
    Role: Co-Principal Investigator
    Biophysical and molecular dialogue of glioma cells and the brain microenvironment
    NIH/NCI U54CA163155Sep 26, 2011 - Jul 31, 2016
    Role: Principal Investigator
    Multipotential mesenchymal stem cell-like cells in pancreatic tumorigenesis
    NIH/NCI R01CA154383Apr 1, 2011 - Mar 31, 2016
    Role: Principal Investigator
    Perivascular Invasion of GBMs
    NIH/NCI R01CA113382Aug 15, 2006 - May 31, 2011
    Role: Principal Investigator
    PDGFRbeta+-Perivascular Cells In Tumor Angiogenesis
    NIH/NCI R01CA109390Aug 1, 2004 - Jul 31, 2009
    Role: Principal Investigator
    Mechanism and therapeutic targeting of evasive resistance to antiangiogenic drugs
    NIH/NCI R01CA099948Feb 11, 2003 - May 31, 2013
    Role: Principal Investigator

    Collapse ORNG Applications 
    Collapse Websites

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. He B, Jabouille A, Steri V, Johansson-Percival A, Michael IP, Kotamraju VR, Junckerstorff R, Nowak AK, Hamzah J, Lee G, Bergers G, Ganss R. Vascular targeting of LIGHT normalizes blood vessels in primary brain cancer and induces intratumoral high endothelial venules. J Pathol. 2018 Mar 30. PMID: 29603739.
      View in: PubMed
    2. Allen E, Missiaen R, Bergers G. Therapeutic induction of high endothelial venules (HEVs) to enhance T-cell infiltration in tumors. Oncotarget. 2017 Nov 21; 8(59):99207-99208. PMID: 29245888.
      View in: PubMed
    3. Jahangiri A, Nguyen A, Chandra A, Sidorov MK, Yagnik G, Rick J, Han SW, Chen W, Flanigan PM, Schneidman-Duhovny D, Mascharak S, De Lay M, Imber B, Park CC, Matsumoto K, Lu K, Bergers G, Sali A, Weiss WA, Aghi MK. Cross-activating c-Met/ß1 integrin complex drives metastasis and invasive resistance in cancer. Proc Natl Acad Sci U S A. 2017 Oct 10; 114(41):E8685-E8694. PMID: 28973887.
      View in: PubMed
    4. Allen E, Jabouille A, Rivera LB, Lodewijckx I, Missiaen R, Steri V, Feyen K, Tawney J, Hanahan D, Michael IP, Bergers G. Combined antiangiogenic and anti-PD-L1 therapy stimulates tumor immunity through HEV formation. Sci Transl Med. 2017 Apr 12; 9(385). PMID: 28404866.
      View in: PubMed
    5. Allen E, Missiaen R, Bergers G. Trimming the Vascular Tree in Tumors: Metabolic and Immune Adaptations. Cold Spring Harb Symp Quant Biol. 2016; 81:21-29. PMID: 28396525.
      View in: PubMed
    6. Hambardzumyan D, Bergers G. Glioblastoma: Defining Tumor Niches. Trends Cancer. 2015 Dec; 1(4):252-265. PMID: 27088132.
      View in: PubMed
    7. Rivera LB, Bergers G. CANCER. Tumor angiogenesis, from foe to friend. Science. 2015 Aug 14; 349(6249):694-5. PMID: 26273044.
      View in: PubMed
    8. Rivera LB, Meyronet D, Hervieu V, Frederick MJ, Bergsland E, Bergers G. Intratumoral myeloid cells regulate responsiveness and resistance to antiangiogenic therapy. Cell Rep. 2015 Apr 28; 11(4):577-91. PMID: 25892230; PMCID: PMC4438771.
      View in: PubMed, PubMed Central
    9. Rivera LB, Bergers G. Intertwined regulation of angiogenesis and immunity by myeloid cells. Trends Immunol. 2015 Apr; 36(4):240-9. PMID: 25770923; PMCID: PMC4393787.
      View in: PubMed, PubMed Central
    10. Wang AS, Lodi A, Rivera LB, Izquierdo-Garcia JL, Firpo MA, Mulvihill SJ, Tempero MA, Bergers G, Ronen SM. HR-MAS MRS of the pancreas reveals reduced lipid and elevated lactate and taurine associated with early pancreatic cancer. NMR Biomed. 2014 Nov; 27(11):1361-70. PMID: 25199993.
      View in: PubMed
    11. Rivera LB, Bergers G. Angiogenesis. Targeting vascular sprouts. Science. 2014 Jun 27; 344(6191):1449-50. PMID: 24970064.
      View in: PubMed
    12. Hyvönen M, Enbäck J, Huhtala T, Lammi J, Sihto H, Weisell J, Joensuu H, Rosenthal-Aizman K, El-Andaloussi S, Langel U, Närvänen A, Bergers G, Laakkonen P. Novel target for peptide-based imaging and treatment of brain tumors. Mol Cancer Ther. 2014 Apr; 13(4):996-1007. PMID: 24493698; PMCID: PMC4007056.
      View in: PubMed, PubMed Central
    13. Rivera L, Pandika M, Bergers G. Escape mechanisms from antiangiogenic therapy: an immune cell's perspective. Adv Exp Med Biol. 2014; 772:83-99. PMID: 24272355.
      View in: PubMed
    14. Rivera LB, Bergers G. Location, location, location: macrophage positioning within tumors determines pro- or antitumor activity. Cancer Cell. 2013 Dec 09; 24(6):687-9. PMID: 24332035; PMCID: PMC4243836.
      View in: PubMed, PubMed Central
    15. Jahangiri A, De Lay M, Miller LM, Carbonell WS, Hu YL, Lu K, Tom MW, Paquette J, Tokuyasu TA, Tsao S, Marshall R, Perry A, Bjorgan KM, Chaumeil MM, Ronen SM, Bergers G, Aghi MK. Gene expression profile identifies tyrosine kinase c-Met as a targetable mediator of antiangiogenic therapy resistance. Clin Cancer Res. 2013 Apr 01; 19(7):1773-83. PMID: 23307858; PMCID: PMC3618605.
      View in: PubMed, PubMed Central
    16. Lu KV, Bergers G. Mechanisms of evasive resistance to anti-VEGF therapy in glioblastoma. CNS Oncol. 2013 Jan; 2(1):49-65. PMID: 23750318; PMCID: PMC3673744.
      View in: PubMed, PubMed Central
    17. Lu KV, Chang JP, Parachoniak CA, Pandika MM, Aghi MK, Meyronet D, Isachenko N, Fouse SD, Phillips JJ, Cheresh DA, Park M, Bergers G. VEGF inhibits tumor cell invasion and mesenchymal transition through a MET/VEGFR2 complex. Cancer Cell. 2012 Jul 10; 22(1):21-35. PMID: 22789536; PMCID: PMC4068350.
      View in: PubMed, PubMed Central
    18. Sugiarto S, Persson AI, Munoz EG, Waldhuber M, Lamagna C, Andor N, Hanecker P, Ayers-Ringler J, Phillips J, Siu J, Lim DA, Vandenberg S, Stallcup W, Berger MS, Bergers G, Weiss WA, Petritsch C. Asymmetry-defective oligodendrocyte progenitors are glioma precursors. Cancer Cell. 2011 Sep 13; 20(3):328-40. PMID: 21907924; PMCID: PMC3297490.
      View in: PubMed, PubMed Central
    19. Dvorak HF, Weaver VM, Tlsty TD, Bergers G. Tumor microenvironment and progression. J Surg Oncol. 2011 May 01; 103(6):468-74. PMID: 21480238; PMCID: PMC3277953.
      View in: PubMed, PubMed Central
    20. Persson AI, Petritsch C, Swartling FJ, Itsara M, Sim FJ, Auvergne R, Goldenberg DD, Vandenberg SR, Nguyen KN, Yakovenko S, Ayers-Ringler J, Nishiyama A, Stallcup WB, Berger MS, Bergers G, McKnight TR, Goldman SA, Weiss WA. Non-stem cell origin for oligodendroglioma. Cancer Cell. 2010 Dec 14; 18(6):669-82. PMID: 21156288; PMCID: PMC3031116.
      View in: PubMed, PubMed Central
    21. Lu KV, Zhu S, Cvrljevic A, Huang TT, Sarkaria S, Ahkavan D, Dang J, Dinca EB, Plaisier SB, Oderberg I, Lee Y, Chen Z, Caldwell JS, Xie Y, Loo JA, Seligson D, Chakravari A, Lee FY, Weinmann R, Cloughesy TF, Nelson SF, Bergers G, Graeber T, Furnari FB, James CD, Cavenee WK, Johns TG, Mischel PS. Fyn and SRC are effectors of oncogenic epidermal growth factor receptor signaling in glioblastoma patients. Cancer Res. 2009 Sep 01; 69(17):6889-98. PMID: 19690143; PMCID: PMC2770839.
      View in: PubMed, PubMed Central
    22. Pàez-Ribes M, Allen E, Hudock J, Takeda T, Okuyama H, Viñals F, Inoue M, Bergers G, Hanahan D, Casanovas O. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell. 2009 Mar 03; 15(3):220-31. PMID: 19249680; PMCID: PMC2874829.
      View in: PubMed, PubMed Central
    23. Bergers G, Hanahan D. Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer. 2008 Aug; 8(8):592-603. PMID: 18650835; PMCID: PMC2874834.
      View in: PubMed, PubMed Central
    24. Silber J, Lim DA, Petritsch C, Persson AI, Maunakea AK, Yu M, Vandenberg SR, Ginzinger DG, James CD, Costello JF, Bergers G, Weiss WA, Alvarez-Buylla A, Hodgson JG. miR-124 and miR-137 inhibit proliferation of glioblastoma multiforme cells and induce differentiation of brain tumor stem cells. BMC Med. 2008 Jun 24; 6:14. PMID: 18577219; PMCID: PMC2443372.
      View in: PubMed, PubMed Central
    25. Du R, Petritsch C, Lu K, Liu P, Haller A, Ganss R, Song H, Vandenberg S, Bergers G. Matrix metalloproteinase-2 regulates vascular patterning and growth affecting tumor cell survival and invasion in GBM. Neuro Oncol. 2008 Jun; 10(3):254-64. PMID: 18359864; PMCID: PMC2563048.
      View in: PubMed, PubMed Central
    26. Du R, Lu KV, Petritsch C, Liu P, Ganss R, Passegué E, Song H, Vandenberg S, Johnson RS, Werb Z, Bergers G. HIF1alpha induces the recruitment of bone marrow-derived vascular modulatory cells to regulate tumor angiogenesis and invasion. Cancer Cell. 2008 Mar; 13(3):206-20. PMID: 18328425; PMCID: PMC2643426.
      View in: PubMed, PubMed Central
    27. Pietras K, Pahler J, Bergers G, Hanahan D. Functions of paracrine PDGF signaling in the proangiogenic tumor stroma revealed by pharmacological targeting. PLoS Med. 2008 Jan 29; 5(1):e19. PMID: 18232728; PMCID: PMC2214790.
      View in: PubMed, PubMed Central
    28. Lu K, Lamagna C, Bergers G. Chapter 3. Bone marrow-derived vascular progenitors and proangiogenic monocytes in tumors. Methods Enzymol. 2008; 445:53-82. PMID: 19022055.
      View in: PubMed
    29. Chesler L, Goldenberg DD, Seales IT, Satchi-Fainaro R, Grimmer M, Collins R, Struett C, Nguyen KN, Kim G, Tihan T, Bao Y, Brekken RA, Bergers G, Folkman J, Weiss WA. Malignant progression and blockade of angiogenesis in a murine transgenic model of neuroblastoma. Cancer Res. 2007 Oct 01; 67(19):9435-42. PMID: 17909053; PMCID: PMC2921769.
      View in: PubMed, PubMed Central
    30. Kawaguchi T, Yamashita Y, Kanamori M, Endersby R, Bankiewicz KS, Baker SJ, Bergers G, Pieper RO. The PTEN/Akt pathway dictates the direct alphaVbeta3-dependent growth-inhibitory action of an active fragment of tumstatin in glioma cells in vitro and in vivo. Cancer Res. 2006 Dec 01; 66(23):11331-40. PMID: 17145879.
      View in: PubMed
    31. Lamagna C, Bergers G. The bone marrow constitutes a reservoir of pericyte progenitors. J Leukoc Biol. 2006 Oct; 80(4):677-81. PMID: 16888086.
      View in: PubMed
    32. Holash J, Thurston G, Rudge JS, Yancopoulos GD, Adjei AA, Bergers G, Pytowski B, Pegram M, Gordon MS. Inhibitors of growth factor receptors, signaling pathways and angiogenesis as therapeutic molecular agents. Cancer Metastasis Rev. 2006 Jun; 25(2):243-52. PMID: 16770536.
      View in: PubMed
    33. Bergers G, Song S. The role of pericytes in blood-vessel formation and maintenance. Neuro Oncol. 2005 Oct; 7(4):452-64. PMID: 16212810; PMCID: PMC1871727.
      View in: PubMed, PubMed Central
    34. Casanovas O, Hicklin DJ, Bergers G, Hanahan D. Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell. 2005 Oct; 8(4):299-309. PMID: 16226705.
      View in: PubMed
    35. Song S, Ewald AJ, Stallcup W, Werb Z, Bergers G. PDGFRbeta+ perivascular progenitor cells in tumours regulate pericyte differentiation and vascular survival. Nat Cell Biol. 2005 Sep; 7(9):870-9. PMID: 16113679; PMCID: PMC2771163.
      View in: PubMed, PubMed Central
    36. Berger M, Bergers G, Arnold B, Hämmerling GJ, Ganss R. Regulator of G-protein signaling-5 induction in pericytes coincides with active vessel remodeling during neovascularization. Blood. 2005 Feb 01; 105(3):1094-101. PMID: 15459006.
      View in: PubMed
    37. Kanamori M, Vanden Berg SR, Bergers G, Berger MS, Pieper RO. Integrin beta3 overexpression suppresses tumor growth in a human model of gliomagenesis: implications for the role of beta3 overexpression in glioblastoma multiforme. Cancer Res. 2004 Apr 15; 64(8):2751-8. PMID: 15087390.
      View in: PubMed
    38. Joyce JA, Laakkonen P, Bernasconi M, Bergers G, Ruoslahti E, Hanahan D. Stage-specific vascular markers revealed by phage display in a mouse model of pancreatic islet tumorigenesis. Cancer Cell. 2003 Nov; 4(5):393-403. PMID: 14667506.
      View in: PubMed
    39. Blouw B, Song H, Tihan T, Bosze J, Ferrara N, Gerber HP, Johnson RS, Bergers G. The hypoxic response of tumors is dependent on their microenvironment. Cancer Cell. 2003 Aug; 4(2):133-46. PMID: 12957288.
      View in: PubMed
    40. Bergers G, Benjamin LE. Tumorigenesis and the angiogenic switch. Nat Rev Cancer. 2003 Jun; 3(6):401-10. PMID: 12778130.
      View in: PubMed
    41. Bergers G, Song S, Meyer-Morse N, Bergsland E, Hanahan D. Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J Clin Invest. 2003 May; 111(9):1287-95. PMID: 12727920; PMCID: PMC154450.
      View in: PubMed, PubMed Central
    42. Man S, Bocci G, Francia G, Green SK, Jothy S, Hanahan D, Bohlen P, Hicklin DJ, Bergers G, Kerbel RS. Antitumor effects in mice of low-dose (metronomic) cyclophosphamide administered continuously through the drinking water. Cancer Res. 2002 May 15; 62(10):2731-5. PMID: 12019144.
      View in: PubMed
    43. Bergers G, Hanahan D. Combining antiangiogenic agents with metronomic chemotherapy enhances efficacy against late-stage pancreatic islet carcinomas in mice. Cold Spring Harb Symp Quant Biol. 2002; 67:293-300. PMID: 12858552.
      View in: PubMed
    44. Bergers G, Brekken R, McMahon G, Vu TH, Itoh T, Tamaki K, Tanzawa K, Thorpe P, Itohara S, Werb Z, Hanahan D. Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat Cell Biol. 2000 Oct; 2(10):737-44. PMID: 11025665; PMCID: PMC2852586.
      View in: PubMed, PubMed Central
    45. Hanahan D, Bergers G, Bergsland E. Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice. J Clin Invest. 2000 Apr; 105(8):1045-7. PMID: 10772648; PMCID: PMC300842.
      View in: PubMed, PubMed Central
    46. Bergers G, Coussens LM. Extrinsic regulators of epithelial tumor progression: metalloproteinases. Curr Opin Genet Dev. 2000 Feb; 10(1):120-7. PMID: 10679388.
      View in: PubMed
    47. Coussens LM, Raymond WW, Bergers G, Laig-Webster M, Behrendtsen O, Werb Z, Caughey GH, Hanahan D. Inflammatory mast cells up-regulate angiogenesis during squamous epithelial carcinogenesis. Genes Dev. 1999 Jun 01; 13(11):1382-97. PMID: 10364156; PMCID: PMC316772.
      View in: PubMed, PubMed Central
    48. Bergers G, Javaherian K, Lo KM, Folkman J, Hanahan D. Effects of angiogenesis inhibitors on multistage carcinogenesis in mice. Science. 1999 Apr 30; 284(5415):808-12. PMID: 10221914.
      View in: PubMed
    49. Vu TH, Shipley JM, Bergers G, Berger JE, Helms JA, Hanahan D, Shapiro SD, Senior RM, Werb Z. MMP-9/gelatinase B is a key regulator of growth plate angiogenesis and apoptosis of hypertrophic chondrocytes. Cell. 1998 May 01; 93(3):411-22. PMID: 9590175; PMCID: PMC2839071.
      View in: PubMed, PubMed Central
    50. Bergers G, Hanahan D, Coussens LM. Angiogenesis and apoptosis are cellular parameters of neoplastic progression in transgenic mouse models of tumorigenesis. Int J Dev Biol. 1998; 42(7):995-1002. PMID: 9853830.
      View in: PubMed
    51. Van Strien T, Rookus MA, Bergers G, Frijters JE, Defares PB. Life events, emotional eating and change in body mass index. Int J Obes. 1986; 10(1):29-35. PMID: 3710686.
      View in: PubMed
    Gabriele's Networks
    Concepts
    Derived automatically from this person's publications.
    See all (271) concept(s)
    _
    Co-Authors
    People in Profiles who have published with this person.
    See all (30) people
    _
    Related Authors
    People who share related concepts with this person.
    See all (60) people
    _
    Back to TOP